Gilead's Remdesivir Cuts Risk of COVID-19 Death by 62% -- Maybe

Gilead Sciences' (NASDAQ: GILD) remdesivir cut the risk of death by 62% in severe COVID-19 patients. While the results, which were presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference, sound great, they come from a retrospective analysis comparing results from two different data sources. The remdesivir mortality rate comes from results of patients in Gilead's phase 3 SIMPLE-Severe clinical trial.